{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:53:44Z","timestamp":1791140024311,"version":"4.1.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We report long-term results of treatment of myelodysplastic syndrome (MDS) with erythropoietin and granulocyte colony-stimulating factor (G-CSF). A total of 129 patients were followed up 45 months after last inclusion in the Nordic MDS Group studies. Erythroid response rate was 39% and median response duration 23 months (range, 3-116 months or more). Complete responders showed longer response duration than partial responders (29 versus 12 months, P = .006). The International Prognostic Scoring System (IPSS) groups Low\/Intermediate-1 (Low\/Int-1) had longer response duration than Int-2\/High (25 versus 7 months, P = .002). The time until 25% developed acute myeloid leukemia (AML) was longer in the good and intermediate predictive groups for erythroid response compared with the poor predictive group (52 versus 13 months, P = .008). Only 1 of 20 long-term responders developed AML. We assessed the effect on long-term outcome by comparing treated patients with untreated patients selected from the IPSS database using multivariate Cox regression, adjusting for major prognostic variables. There was no difference in survival (odds ratio [OR], 0.9; 95% confidence interval [CI], 0.7-1.2; P = .55) or risk of AML evolution (OR, 1.3; 95% CI, 0.7-2.2; P = .40) between treated and untreated patients. Patients with high\/intermediate probability of response and with IPSS Low\/Int-1 show frequent and durable responses without adverse effects on outcome, while other patients should not be considered candidates for this treatment.<\/jats:p>","DOI":"10.1182\/blood-2004-10-3872","type":"journal-article","created":{"date-parts":[[2005,4,19]],"date-time":"2005-04-19T20:24:41Z","timestamp":1113942281000},"page":"803-811","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":169,"title":["Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF"],"prefix":"10.1182","volume":"106","author":[{"given":"Martin","family":"Ja\u0308dersten","sequence":"first","affiliation":[{"name":"From the Karolinska Institutet, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden; Karolinska Institutet, Department of Medicine, Clinical Epidemiology Unit, and Department of Pathology, Karolinska University Hospital Solna, Stockholm, Sweden; Clinical Research Centre, O\u0308rebro University Hospital, Sweden; and Department of Medicine, St Olavs Hospital, Trondheim University Hospital, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Montgomery","sequence":"additional","affiliation":[{"name":"From the Karolinska Institutet, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden; Karolinska Institutet, Department of Medicine, Clinical Epidemiology Unit, and Department of Pathology, Karolinska University Hospital Solna, Stockholm, Sweden; Clinical Research Centre, O\u0308rebro University Hospital, Sweden; and Department of Medicine, St Olavs Hospital, Trondheim University Hospital, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingunn","family":"Dybedal","sequence":"additional","affiliation":[{"name":"From the Karolinska Institutet, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden; Karolinska Institutet, Department of Medicine, Clinical Epidemiology Unit, and Department of Pathology, Karolinska University Hospital Solna, Stockholm, Sweden; Clinical Research Centre, O\u0308rebro University Hospital, Sweden; and Department of Medicine, St Olavs Hospital, Trondheim University Hospital, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Porwit-MacDonald","sequence":"additional","affiliation":[{"name":"From the Karolinska Institutet, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden; Karolinska Institutet, Department of Medicine, Clinical Epidemiology Unit, and Department of Pathology, Karolinska University Hospital Solna, Stockholm, Sweden; Clinical Research Centre, O\u0308rebro University Hospital, Sweden; and Department of Medicine, St Olavs Hospital, Trondheim University Hospital, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hellstro\u0308m-Lindberg","sequence":"additional","affiliation":[{"name":"From the Karolinska Institutet, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden; Karolinska Institutet, Department of Medicine, Clinical Epidemiology Unit, and Department of Pathology, Karolinska University Hospital Solna, Stockholm, Sweden; Clinical Research Centre, O\u0308rebro University Hospital, Sweden; and Department of Medicine, St Olavs Hospital, Trondheim University Hospital, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223395987000_REF1","unstructured":"Jadersten M, Montgomery SM, Astermark J, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor and erythropoietin: response and impact on survival in a long-term follow-up of 129 patients [abstract]. Blood.2003;102: 184a-185a."},{"key":"2020021223395987000_REF2","doi-asserted-by":"crossref","unstructured":"Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol.2003;120: 1037-1046.","DOI":"10.1046\/j.1365-2141.2003.04153.x"},{"key":"2020021223395987000_REF3","doi-asserted-by":"crossref","unstructured":"Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol.1982;51: 189-199.","DOI":"10.1111\/j.1365-2141.1982.tb08475.x"},{"key":"2020021223395987000_REF4","unstructured":"Jaffe E, Harris N, Stein H, et al, eds. WHO Classification of Tumours: Pathology and Genetics of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001."},{"key":"2020021223395987000_REF5","doi-asserted-by":"crossref","unstructured":"Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood.1997;89: 2079-2088.","DOI":"10.1182\/blood.V89.6.2079"},{"key":"2020021223395987000_REF6","doi-asserted-by":"crossref","unstructured":"Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood.1998;92: 68-75.","DOI":"10.1182\/blood.V92.1.68.413k23_68_75"},{"key":"2020021223395987000_","doi-asserted-by":"crossref","unstructured":"Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood.1996;87: 4076-4081.","DOI":"10.1182\/blood.V87.10.4076.bloodjournal87104076"},{"key":"2020021223395987000_REF8","doi-asserted-by":"crossref","unstructured":"Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood.2004;104: 321-327.","DOI":"10.1182\/blood-2003-07-2252"},{"key":"2020021223395987000_REF9","doi-asserted-by":"crossref","unstructured":"Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol.1997;99: 344-351.","DOI":"10.1046\/j.1365-2141.1997.4013211.x"},{"key":"2020021223395987000_REF10","doi-asserted-by":"crossref","unstructured":"Tehranchi R, Fadeel B, Forsblom AM, et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood.2003;101: 1080-1086.","DOI":"10.1182\/blood-2002-06-1774"},{"key":"2020021223395987000_REF11","doi-asserted-by":"crossref","unstructured":"Hellstrom-Lindberg E, Kanter-Lewensohn L, Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res.1997;21: 415-425.","DOI":"10.1016\/S0145-2126(96)00110-5"},{"key":"2020021223395987000_REF12","doi-asserted-by":"crossref","unstructured":"Kelley LL, Koury MJ, Bondurant MC, Koury ST, Sawyer ST, Wickrema A. Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: a mechanism for controlled rates of erythrocyte production. Blood.1993;82: 2340-2352.","DOI":"10.1182\/blood.V82.8.2340.2340"},{"key":"2020021223395987000_REF13","doi-asserted-by":"crossref","unstructured":"Hellstrom-Lindberg E, Birgegard G, Carlsson M, et al. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma.1993;11: 221-228.","DOI":"10.3109\/10428199309086999"},{"key":"2020021223395987000_REF14","doi-asserted-by":"crossref","unstructured":"Mantovani L, Lentini G, Hentschel B, et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol.2000;109: 367-375.","DOI":"10.1046\/j.1365-2141.2000.02016.x"},{"key":"2020021223395987000_REF15","unstructured":"Greenberg P, Taylor K, Larson R, et al. Phase-III randomized multicenter trial of G-CSF vs observation for myelodysplastic syndromes (MDS) [abstract]. Blood.1993;82: 196a."},{"key":"2020021223395987000_REF16","doi-asserted-by":"crossref","unstructured":"Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellstrom-Lindberg E. The WHO classification of MDS does make a difference. Blood.2004;103: 3265-3270.","DOI":"10.1182\/blood-2003-06-2124"},{"key":"2020021223395987000_REF17","doi-asserted-by":"crossref","unstructured":"Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood.2004;104: 321-327.","DOI":"10.1182\/blood-2003-07-2252"},{"key":"2020021223395987000_REF18","unstructured":"Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood.2000;96: 3671-3674."},{"key":"2020021223395987000_REF19","doi-asserted-by":"crossref","unstructured":"Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol.2003;120: 187-200.","DOI":"10.1046\/j.1365-2141.2003.03907.x"},{"key":"2020021223395987000_","unstructured":"Alessandrino EP, Amadori S, Barosi G, et al. - Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica.2002;87: 1286-1306."},{"key":"2020021223395987000_REF21","doi-asserted-by":"crossref","unstructured":"Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood.2002;100: 2303-2320.","DOI":"10.1182\/blood-2002-06-1767"},{"key":"2020021223395987000_REF22","doi-asserted-by":"crossref","unstructured":"Terpos E, Mougiou A, Kouraklis A, et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol.2002;118: 174-180.","DOI":"10.1046\/j.1365-2141.2002.03583.x"},{"key":"2020021223395987000_REF23","doi-asserted-by":"crossref","unstructured":"Musto P, Falcone A, Sanpaolo G, et al. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br J Haematol.2003;122: 269-271.","DOI":"10.1046\/j.1365-2141.2003.04435.x"},{"key":"2020021223395987000_REF24","doi-asserted-by":"crossref","unstructured":"Hubel K, Engert A. Clinical applications of granulocyte colony-stimulating factor: an update and summary. Ann Hematol.2003;82: 207-213.","DOI":"10.1007\/s00277-003-0628-y"},{"key":"2020021223395987000_REF25","doi-asserted-by":"crossref","unstructured":"Wallvik J, Stenke L, Bernell P, Nordahl G, Hippe E, Hast R. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur J Haematol.2002;68: 180-185.","DOI":"10.1034\/j.1600-0609.2002.01530.x"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/3\/803\/1711954\/zh801505000803.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/3\/803\/1711954\/zh801505000803.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T20:43:17Z","timestamp":1586205797000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/3\/803\/21873\/Longterm-outcome-of-treatment-of-anemia-in-MDS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,1]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-10-3872","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.8259.465754","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,1]]}}}